Akari Therapeutics PLC

NASDAQ:AKTXUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.

Contact Information

Headquarters

22 BOSTON WHARF ROAD, FL 7BOSTON, MA, United States 02210

Phone

646-350-0702

Fax

646-843-9352

Executives

Non-Executive Chairman of the Board

Raymond Prudo-chlebosz

President, Chief Executive Officer, Director

Rachelle Jacques

Interim Chief Financial Officer

Wendy Dicicco

Chief Operating Officer

Melissa Bradford-klug

Senior Vice President - Regulatory Affairs

Bethanne Lang